Page last updated: 2024-11-05

trapidil and Cardiac Hypertrophy

trapidil has been researched along with Cardiac Hypertrophy in 1 studies

Trapidil: A coronary vasodilator agent.

Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.

Research Excerpts

ExcerptRelevanceReference
"Trapidil has been described to improve the redox balance and cardiac conditions."1.48Trapidil improves hemodynamic, echocardiographic and redox state parameters of right ventricle in monocrotaline-induced pulmonary arterial hypertension model. ( Belló-Klein, A; Carraro, CC; Colombo, R; da Rosa Araujo, AS; de Lima-Seolin, BG; Lacerda, DS; Poletto Bonetto, JH; Schenkel, PC; Teixeira, RB; Türck, P, 2018)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Türck, P1
Lacerda, DS1
Carraro, CC1
de Lima-Seolin, BG1
Teixeira, RB1
Poletto Bonetto, JH1
Colombo, R1
Schenkel, PC1
Belló-Klein, A1
da Rosa Araujo, AS1

Other Studies

1 other study available for trapidil and Cardiac Hypertrophy

ArticleYear
Trapidil improves hemodynamic, echocardiographic and redox state parameters of right ventricle in monocrotaline-induced pulmonary arterial hypertension model.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 103

    Topics: Animals; Blood Pressure; Calcium; Cardiac Catheterization; Cardiomegaly; Disease Models, Animal; Ech

2018